Regeneron Sustainability Profile
Regeneron Pharmaceuticals, Inc., commonly referred to as Regeneron, is a leading biotechnology company headquartered in the United States. Founded in 1988, Regeneron has established itself as a pioneer in the development of innovative medicines, particularly in the fields of ophthalmology, oncology, and immunology. With a strong focus on research and development, Regeneron is renowned for its unique products, including EYLEA® for eye diseases and Dupixent® for various allergic conditions. The company’s commitment to scientific excellence has positioned it as a key player in the biopharmaceutical industry, achieving significant milestones such as the rapid development of treatments during public health emergencies. Regeneron continues to expand its global footprint, with major operations across North America and Europe, solidifying its reputation as a leader in advancing healthcare solutions.
DitchCarbon Score
How does Regeneron's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Regeneron's score of 57 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Regeneron's reported carbon emissions
In 2024, Regeneron Pharmaceuticals, Inc. reported total emissions of approximately 1,465,520,000 kg CO2e, which includes 80,250,631 kg CO2e from Scope 1 and 40,391,544 kg CO2e from Scope 2 emissions. The company has not disclosed Scope 3 emissions for this year. Regeneron has set ambitious climate commitments, aiming to match 100% of its electricity consumption with certified renewable energy sources by 2035 for both Scope 1 and Scope 2 emissions. Additionally, the company targets a 30% reduction in combined Scope 1 and 2 GHG emissions per square meter by 2025, using a 2016 peak baseline as a reference. The emissions data is sourced directly from Regeneron Pharmaceuticals, Inc., with no cascaded data from a parent or related organization. The company is actively working towards its climate goals, demonstrating a commitment to sustainability and reducing its carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 39,400,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 25,300,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 288,800,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
How Carbon Intensive is Regeneron's Industry?
How Carbon Intensive is Regeneron's Location?
Regeneron's Scope 3 Categories Breakdown
Regeneron's Scope 3 emissions, which increased by 54% last year and increased by approximately 366% since 2016, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 82% of Scope 3 emissions.
Top Scope 3 Categories
Regeneron's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Regeneron has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Boehringer Ingelheim International GmbH
Reckitt
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.